KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trials.

Ana Maria Giménez-Arnau, Artem Zharkov, Bin Yang, Atsushi Fukunaga, Michihiro Hide, Martin Metz, Giselle Mosnaim, Petra Staubach, Xing-Hua Gao, Vipul Jain, Alis Burciu, Bruno Cenni, Sibylle Haemmerle, Merin Kuruvilla, Songqiao Huang, David Ledieu, Jens Schuemann, Emil Scosyrev, Rahel Schneider, Elodie Incera, Karine Lheritier, Hanns-Christian Tillmann, Hichem Zouater, Sarbjit Saini

J Allergy Clin Immunol Pract S2213-2198(26)00445-9

PMID42242425
PMCID-
DOI10.1016/j.jaip.2026.05.027
发表日期2026-06-04
摘要

摘要

BACKGROUND: Remibrutinib, an oral, highly selective Bruton's tyrosine kinase inhibitor (BTKi), showed sustained efficacy in phase 3 REMIX trials in chronic spontaneous urticaria. OBJECTIVE: To report detailed safety outcomes from the REMIX trials, including key findings pertinent to BTKi safety, such as bleeding, infections, cytopenia, and liver safety. METHODS: This was a pooled analysis of REMIX-1 and REMIX-2 consisting of a 24-week, randomized, double-blind, placebo-controlled period, followed by a 28-week open-label treatment period. Adverse event (AE) frequencies and laboratory parameters were examined through week 52, and differences vs placebo were evaluated in the controlled period. RESULTS: AE frequencies and risk differences (95% confidence intervals) for remibrutinib (n=606) vs placebo (n=306) were as follows: any AE 64.9% vs 64.7%, difference 0.1% (-6.4%, 6.7%); bleeding (including laboratory abnormalities) 10.6% vs 5.2%, difference 5.3% (1.6%, 8.7%); infections 33.5% vs 34.3%, difference -0.8% (-7.4%, 5.6%); cytopenia AEs 3.6% vs 2.0%, difference 1.7% (-0.7%, 3.8%); hepatic disorders 3.3% vs 4.9%, difference -1.6% (-4.6%, 1.1%). Imbalance in bleeding was due to petechia and similar mucocutaneous events (predominantly mild, none severe) occurring in 9.1% of patients on remibrutinib vs 2.0% of patients on placebo. No other AEs with significantly increased frequency occurred on remibrutinib. Findings during the entire study period were consistent with those in the controlled period. CONCLUSION: Remibrutinib showed a favorable safety profile with slightly higher incidence of petechia and similar predominantly mild mucocutaneous events. There were no notable differences in the frequency of other safety outcomes between remibrutinib and placebo in the REMIX trials.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。